Company profile
NOVARTIS AG
NYSE:NVSBiotechnology: Pharmaceutical Preparations
Drug pipeline (254)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Acetaminophen | approved | — | 78 | approved |
| Acetylcholine chloride | approved | — | 0 | — |
| ACETYLDIGITOXIN | approved | — | 0 | — |
| ALISKIREN HEMIFUMARATE | approved | — | 0 | — |
| Aluminum hydroxide | approved | — | 0 | — |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (3120)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00219011 | phase3 | completed | 2005-05-01 | 2007-02-01 | Novartis | "ALOFT - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure |
| NCT01197300 | phase3 | completed | 2010-10-25 | 2019-02-27 | Novartis Pharmaceuticals | 1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids |
| NCT02756650 | phase2 | completed | 2016-06-23 | 2019-01-31 | Novartis Pharmaceuticals | 1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement |
| NCT00929110 | phase3 | completed | 2009-06-01 | 2011-04-01 | Novartis | 1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD) |
| NCT01843348 | phase3 | completed | 2012-12-27 | 2016-03-23 | Novartis Pharmaceuticals | 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients |
FDA applications (208)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| ANDA 062480 | ANDA | NOVARTIS PHARMACEUTICALS CORP | ||||
Loading… | ||||||
| ANDA 062501 | ANDA | NOVARTIS PHARMACEUTICALS CORP | ||||
Loading… | ||||||
| ANDA 062544 | ANDA | NOVARTIS PHARMACEUTICALS CORP | ||||
Loading… | ||||||
| ANDA 062566 | ANDA | NOVARTIS PHARMACEUTICALS CORP | ||||
Loading… | ||||||
| ANDA 070185 | ANDA | NOVARTIS PHARMACEUTICALS CORP | ||||
Loading… | ||||||